FDA extends review period for Humacyte’s vascular trauma treatment ATEV
The U.S. Food and Drug Administration’s review of Humacyte, Inc.'s innovative vascular trauma treatment, known as the acellular tissue engineered vessel (ATEV), has hit an ... Read More
Humacyte to merge with Alpha Healthcare Acquisition Corp in $1.1bn deal to advance regenerative medicine
Humacyte, Inc., a clinical-stage biotech company based in Durham, North Carolina, has announced a merger with Alpha Healthcare Acquisition Corp. (AHAC), a blank check company. ... Read More
Humacyte begins phase 2 Humacyl vascular trauma trial
Humacyl vascular trauma trial : Humacyte, a regenerative medical technology company, has started a phase 2 clinical trial of its investigational human acellular vessel (HAV) ... Read More